Biovie (Nasdaq: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, announced that a poster detailing the genetic basis for how its drug candidate NE3107 regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements will be presented this weekend at the Alzheimer’s Associate’s International Conference (AAIC) to be held in Amsterdam July 16-20, 2023.

American Resources’ (Nasdaq: AREC) wholly owned subsidiary, ReElement Technologies LLC, a leading provider of high performance refining capacity of battery and rare earth elements, announced it has taken a controlling interest in the former RCA Thomson plant in Marion, Indiana, comprising 425,000 square feet manufacturing capacity on a 42 acre total campus for ReElement Technologies' rare earth and battery material refining.

Aridis (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act for AR-301, a fully human IgG1 monoclonal antibody (mAb) currently in Phase 3 clinical development as an adjunctive therapy for pneumonia caused by gram-positive Staphylococcus aureus in critically ill hospitalized patients.

BullFrog AI (Nasdaq: BFRG), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced the appointment of Enrique García-Rivera, Ph.D., as its new Vice President of Artificial Intelligence. The appointment will further advance BullFrog AI’s best-in-class proprietary bfLEAP™ AI platform that is engineered to enable more accurate predictions of patient disease progression and improve the design of clinical trials to speed safe and effective drug development.